The bill aims to safeguard national security by prohibiting government agencies from contracting with certain biotech providers, but it allows exceptions under specific conditions. It mandates evaluations and designations of concerning biotech companies and implements guidance for these requirements. The bill also addresses the security risks of foreign adversaries collecting American multiomic data, requiring intelligence reports and overseeing company designations. It stresses the revision of regulations to comply with the bill and requires comprehensive reporting on intelligence-related to nefarious activities with multiomic data. No extra funds are authorized for these measures, and the bill includes specific definitions for its terms.